The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
Open accessAbstract
A trial fibrillation (AF) and valvular heart disease frequently coexist and independently increase mortality.1 Bioprosthetic valve implantation (surgical or transcatheter) is a common, increasingly utilized treatment for valvular heart disease. 2 Patients with AF and bioprosthetic valves require anticoagulation to prevent thromboembolic events.Non-vitamin K oral anticoagulants are safe and efficacious alternatives to vitamin K antagonists for anticoagulation in AF.However, guidelines recommend against using non-vitamin K oral anticoagulants in patients with bioprosthetic valves, citing a lack of supporting data.Only 1 of the first 3 warfarin-controlled pivotal non-vitamin K oral anticoagulants trials in AF included patients with bioprosthetic valves (n>80).3 The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48), which compared edoxaban (a direct oral factor Xa inhibitor) to warfarin in patients with AF, 4 did not exclude patients with bioprosthetic valves, thus providing an opportunity to analyze this high-risk subgroup.ENGAGE AF-TIMI 48 randomized patients with AF and a CHADS 2 score (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke or TIA [2 points]) ≥2 to a once daily higher dose edoxaban regimen (60 mg), lower dose edoxaban regimen (30 mg), or warfarin (International Normalized Ratio target of 2.0-3.0).The edoxaban dose was reduced by 50% in patients with decreased clearance.Patients with a history of left-sided valvular heart disease, 5 including those with a history of aortic or mitral bioprosthetic valve implantation (either surgical or transcatheter) >30 days before randomization, were analyzed because right-sided valvular heart disease rarely causes stroke.The indication and date of bioprosthetic valve implantation were not collected.Patients with mechanical valves or moderate-severe mitral stenosis were excluded.The ENGAGE AF-TIMI 48 protocol and amendments were approved by the ethics committee at each participating center.All participants provided written informed consent.The study was registered with ClinicalTrials.gov(unique identifier: NCT00781391) and can be found at https://clinicaltrials.gov/ct2/show/ NCT00781391.In this prespecified analysis, we evaluated outcomes with edoxaban versus warfarin in patients with bioprosthetic valves enrolled in ENGAGE AF-TIMI 48.Primary end points included stroke or systemic embolic events (stroke/SEE), major bleeding (per the International Society for Thrombosis and Haemostasis definition), and the primary net clinical outcome (stroke/SEE, major bleeding, death).Secondary composite end points included ischemic stroke/SEE, major adverse cardiac events (myocardial infarction, stroke, or cardiovascular death), and the composite of stroke/SEE, all-cause mortality, and life-threatening or fatal bleeding (alternative net clinical outcome).An independent, blinded clinical end point committee adjudicated all clinical end points as defined in the main trial.Baseline patient characteristics were described, and hazard ratios (HRs) for each end point comparing higher and lower dose edoxaban to warfarin were calculated.Of 21 105 patients enrolled in the main trial, 191 (0.9%) had previous bioprosthetic valve implantation (n=131 [68.6%] mitral, n=60 [31.4%] aortic).The median follow-up
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Cited by
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 1,982
Metadata
- Authors
- Carnicelli, A. P., De Caterina, R., Halperin, J. L., Renda, G., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E., & Giugliano, R. P.
- Venue
- Circulation
- Published
- 2017-03-28
- Volume
- 135
- Issue
- 13
- Pages
- 1273-1275
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2588405059
- Cited by
- 166
- References
- 2
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. https://app.cochat.ai/papers/10.1161/circulationaha.116.026714
- The paper
- Carnicelli, A. P., De Caterina, R., Halperin, J. L., Renda, G., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E., & Giugliano, R. P. (2017). Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. https://doi.org/10.1161/circulationaha.116.026714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.